|
06/02/2023
|
Summary ToggleEledon Pharmaceuticals to Present at Jefferies Healthcare Conference
|
|
05/11/2023
|
Summary ToggleEledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
|
|
05/04/2023
|
Summary ToggleEledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
|
|
05/01/2023
|
Summary ToggleEledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
|
|
03/31/2023
|
Summary ToggleEledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
|
|
03/30/2023
|
Summary ToggleEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
|
|
03/23/2023
|
Summary ToggleEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
|
|
03/23/2023
|
Summary ToggleEledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
|
|
02/08/2023
|
Summary ToggleEledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
|
|
01/09/2023
|
Summary ToggleeGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
|
